Antigen News and Research

RSS

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week’s DNA Vaccines 2010 in New Orleans, LA concerning the formulation and topical administration of the DermaVir therapeutic vaccine for HIV/AIDS. DNA Vaccine 2010 invites leading scientists to report on the latest research in the progressive field of DNA or Genetic Vaccines.

3 Mar 2010

Inovio Biomedical introduces new CELLECTRA-SP series of hand-held, cordless electroporation devices

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA.

3 Mar 2010

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Robotic surgical technology with its three-dimensional, high-definition view gives surgeons the sensation of touch, even as they operate from a remote console. A new study describes the phenomenon, called intersensory integration, and reports that surgical outcomes for prostate cancer surgery using minimally invasive robotic technology compare favorably with traditional invasive surgery.

3 Mar 2010

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT Southwestern Medical Center.

3 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

2 Mar 2010

Intercell AG's revenues for full year 2009 increase 10.6%

Today, the biotech-vaccine company Intercell AG announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.

2 Mar 2010

AdMeTech Foundation: Health care reform highlights need for better screening and prevention of prostate cancer

AdMeTech Foundation announced today that its President and CEO Dr. Faina Shtern will testify on March 4 before the U.S. House Committee on Oversight and Government Reform on how health care reform highlights the need for increased funding for research aimed at creating accurate, life-saving diagnostic tools for prostate cancer, which will improve screening, prevention, early detection and reduce health costs.

2 Mar 2010

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

SIMPLE Antibody(TM) Platform Delivers Unprecedented Choice of Ultra-Potent Functional Antibody Leads Against Challenging Soluble and Cell Surface Targets. - ARGX-109, a Fully Human mAb Targeting Autoimmune, Inflammation and Oncology Indications, Enters Preclinical Development in Less Than 12 Months From Start of Discovery.

1 Mar 2010

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

HIV/AIDS remains one of the world's most significant public health challenges, particularly in developing countries. The Human Immunodeficiency Virus (HIV-1), the variant responsible for the pandemic, has the ability to infect different cell types such as T cells, macrophages and dendritic cells (DC). These latter cells are crucial in the defense against infectious agents and play a major role in viral pathogenesis.

25 Feb 2010

PharmAthene awarded total of $78.4M in additional funding to develop SparVax vaccine

PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority has modified its existing research and development contract with PharmAthene providing for up to a total of $78.4 million in additional funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government, to support the continued advanced development of SparVax™, a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National Stockpile.

24 Feb 2010

Nitric oxide may play key role in the pathogenesis of neonatal meningitis

Current research suggests that nitric oxide may play a role in the pathogenesis of neonatal meningitis. The related report by Mittal et al, "Inhibition of inducible nitric oxide controls pathogen load and brain damage by enhancing phagocytosis of Escherichia coli K1 in neonatal meningitis," appears in the March 2010 issue of The American Journal of Pathology.

24 Feb 2010

Genocea Biosciences secures licensing to extensive HSV antigen patent estate

Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has licensed an extensive patent estate from the University of Washington and the Fred Hutchinson Cancer Research Center for 25 pending and issued patents related to herpes simplex virus (HSV) type 2 antigens. The addition of these patents complements the novel antigens discovered by Genocea’s unique and proprietary antigen discovery technology. The combination of Genocea’s novel intellectual property with the patent estate from the University of Washington provides the Company with a broad compendium of HSV antigen patents.

24 Feb 2010

GlycoVaxyn initiates Phase I clinical study of GVXN SD133 vaccine candidate against Shigella dysenteriae

GlycoVaxyn, a pioneer in the development of innovative bioconjugate vaccines, has commenced a Phase I clinical study with its vaccine candidate (GVXN SD133) against Shigella dysenteriae, a cause of serious intestinal infections. This is the first product from the company to enter clinical evaluation.

23 Feb 2010

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

Gene study provides new clues to fight infections

Investigators at The Methodist Hospital Research Institute in Houston examined for the first time the long-term response to strep throat on a genome-wide level, shedding light on how group A streptococcus interacts with the patient's immune system and attempts to circumvent it.

23 Feb 2010

Nation-wide study to assess risk of suicide among men

The introduction of prostate-specific antigen (PSA) testing as a screening tool for early detection of prostate cancer (PCa) in the beginning of the 1990s drastically increased the detection of PCa. The risk of suicide is increased among cancer patients including men with PCa.

23 Feb 2010

Emerging concepts from gene regulation studies in immune cells

The seventh meeting in the “Emergence and Convergence” series jointly organized by La Fondation IPSEN and Nature brings together today in San Antonio (Texas, USA) leading experts to discuss concepts emerging from gene regulation studies in immune cells that have led to insights into the initiation and maintenance of epigenetic chromatin marks necessary for proper differentiation and function of these cells in the immune system.

19 Feb 2010

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies for serious human diseases such as HIV and cardiovascular diseases, announced results from its prophylactic HIV vaccine (VRX1023) study in Rhesus Macaque monkeys during a presentation today at the 2010 Annual Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, CA.

19 Feb 2010

Gentel Biosciences launches integrated Proteomics Multi-System

Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing “scan-to-analysis” functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.

19 Feb 2010

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

New results from a phase II clinical trial of the prostate cancer drug abiraterone suggest that it may help men with advanced disease who have tried standard treatments.

17 Feb 2010

Antigen News and Research

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Inovio Biomedical introduces new CELLECTRA-SP series of hand-held, cordless electroporation devices

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

Intercell AG's revenues for full year 2009 increase 10.6%

AdMeTech Foundation: Health care reform highlights need for better screening and prevention of prostate cancer

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

PharmAthene awarded total of $78.4M in additional funding to develop SparVax vaccine

Nitric oxide may play key role in the pathogenesis of neonatal meningitis

Genocea Biosciences secures licensing to extensive HSV antigen patent estate

GlycoVaxyn initiates Phase I clinical study of GVXN SD133 vaccine candidate against Shigella dysenteriae

Study shows CEL-2000 vaccine blocks RA progression in mice

Gene study provides new clues to fight infections

Nation-wide study to assess risk of suicide among men

Emerging concepts from gene regulation studies in immune cells

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

Gentel Biosciences launches integrated Proteomics Multi-System

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News